BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Oura’s IPO is shaping up as the week’s biggest consumer-tech test. The Finnish smart-ring maker begins trading on Nasdaq under ticker OURA this week, with pricing expected Sept. 29 after a roadshow that kicked off Sept. 21.
What happened
Oura Health Oy is offering 50 million shares at $40–$44 each, targeting a raise of up to $2.2 billion. At the top of the range, the fully diluted valuation comes in at roughly $15.62 billion (per Reuters), or about $14.1 billion on outstanding shares (per Bloomberg).
The deal is heavily secondary: only 13.5 million shares are new, with 36.5 million — roughly 73% — sold by existing shareholders, plus a 7.5 million-share overallotment option for underwriters. Demand looks strong: the offering was reportedly about 4x oversubscribed ahead of pricing.
Key figures:
- $2.2B — maximum targeted raise; 50M shares at $40–$44
- $15.62B — implied fully diluted valuation at the top of the range
- $1.21B — revenue for the nine months ended June 30, up 74% year over year
- 3.6M — devices sold in the 12 months ended June 30
- $240.5M — subscription revenue, up 121% YoY
Cornerstone demand includes Eli Lilly, which indicated interest in up to $100 million of IPO shares. Lilly already holds a $50 million stake and partners with Oura on biometric tracking. Dragoneer may take up to $300 million, while Fidelity holds more than 10%.
Why it matters
This is the clearest test yet of IPO appetite for consumer tech at a moment of AI-spending uncertainty and Fed-policy anxiety. The headline question is valuation: roughly 15x trailing sales puts Oura in rare territory for a hardware business.
The bull case is that Oura isn’t really hardware anymore. Rings that track sleep, heart rate, stress and recovery feed a subscription engine growing at 121%, and the company expects about 5.7 million paid members by the end of fiscal 2026, up from 5 million at June 30. The bear case: a 73% secondary component means most of the raise enriches insiders rather than funding growth — a classic late-cycle tell worth watching.
What to watch
Pricing on Sept. 29 and first-day trading will set the tone for the rest of the IPO calendar. Watch how underwriters Goldman Sachs, Morgan Stanley and J.P. Morgan allocate shares, whether the stock holds above the range on day one, and what the paid-member trajectory says about durability. A strong debut reopens the window for consumer IPOs; a stumble confirms buyers are being picky.
Related reading: Solidigm IPO: SK Hynix Unit Eyes $150B Listing, Largest Chip IPO Ever — another big-name listing testing public-market appetite, this time for AI storage.
Sources: Pulse 2; Phemex; TickerTalk
Auto-posted by the Bull Lounge news desk. Not financial advice.
At roughly 15x sales, is Oura priced as a hardware company or a health-data platform — and which would you rather pay for?
Log in to vote
